



# Biotech Daily

Tuesday May 25, 2010

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH DOWN: LBT UP 6%; CELLMID DOWN 9%**
- \* **XENOME APPOINTS PEPLIN'S MICHAEL ALDRIDGE EXECUTIVE DIRECTOR**
- \* **TEAM-VIC'S TISSUE ENGINEERING SEMINAR BLITZ**
- \* **STIRLING ADDS KIDNEY HEALTH TO HIV, TB, 'FLU OTC PRODUCT LIST**
- \* **CHINA APPROVES CYCLOPHARM TECHNEGAS PLUS GENERATOR**
- \* **BIOPROSPECT DEVELOPS NATURAL THERAPIES, EMU OIL**

## MARKET REPORT

The Australian stock market tumbled 2.96 percent on Tuesday May 25, 2010 with the S&P ASX 200 falling 130.1 points to 4265.3 points.

Five of the Biotech Daily Top 40 stocks were up, 21 fell, 11 traded unchanged and three were untraded.

LBT Innovations was best, up half a cent or 6.25 percent to 8.5 cents with 35,200 shares traded, followed by Cathrx, Heartware and Sunshine Heart up more than three percent; with Clinuvel and Resmed up more than one percent.

Cellmid led the falls, down 0.2 cents or 8.7 percent to 2.1 cents with 266,666 shares traded, followed by Phosphagenics down 1.5 cents or 8.6 percent to 16 cents with 1.5 million shares traded.

Biota lost 7.9 percent; Antisense, Prana and Viralytics were down more than six percent; Mesoblast, Novogen and Prana fell more than four percent; Cellestis, Chemgenex, Impedimed, Prima and QRX were down more than three percent; Nanosonics and Tissue Therapies shed more than two percent; with Bionomics, CSL, Sirtex and Universal Biosensors down more than one percent.

## XENOME

Xenome has appointed former Peplin chief executive officer Michael Aldridge to replace Dr Ian Nisbet as executive director.

Xenome said the San Francisco-based Mr Aldridge had an extensive background in biotechnology and pharmaceutical “having held leadership, strategic, consulting and financing roles in North American, European and Australian companies”.

Xenome said Mr Aldridge was chief executive officer, a director and consultant with Peplin from 2003 to 2009.

In that time he took Peplin to a US Food and Drug Administration-approved phase III trial for Peplin’s PEP-005 gel for actinic keratoses and other precancerous skin lesions.

After Mr Aldridge was replaced as Peplin’s chief executive officer by chairman Tom Wiggans in August 2008, the company was sold to Leo Pharma for \$US287.5 million in September 2009 (BD: Aug 19, 2008; Sep 3, 2009).

Xenome chairman Jim Hazel said the company was “delighted to have recruited Michael Aldridge to join Xenome”.

Xenome said it was in the process of initiating a Xen2174 phase II study in post-operative pain.

Xenome is a public unlisted company.

## TISSUE ENGINEERING AND MATRIX GROUP OF VICTORIA

The Tissue Engineering and Matrix group of Victoria (TEAM-Vic) will hold a Seminar Blitz with a selection of academia, industry and clinical institutes of Victoria.

O’Brien Institute business development manager Dr Buzz Palmer said TEAM-Vic was an initiative providing a networking community for researchers, industry, government, funding agencies, media, regulators and clinicians in Victoria.

Dr Palmer said TEAM-Vic wanted to promote “a successful and sustainable tissue engineering and regenerative medicine industry in Victoria”.

The network is of particular interest to those engaged in the translation of research into clinical applications and all aspects of new regenerative medicine technologies, Dr Palmer said.

Dr Palmer said tissue engineering and regenerative medicine held the promise of groundbreaking therapies for patients, bringing together a variety of emerging disciplines hoping to improve the health and quality of life for millions of people worldwide.

The meeting will have seven five-minute speakers including the O’Brien Institute’s Dr Phillip Marzella, the Commonwealth Scientific and Industrial Research Organisation’s Dr John Ramshaw, the Geelong Hospital’s Dr Gil Stynes, IXC Intermediary’s Dr Chris Vearing, Monash University’s Dr Qizhi Chen, Minifab’s Dr Dusan Milojevic and the National Trauma Research Institute at the Alfred Hospital’s Dr Cristina Morganti-Kossmann. The Seminar Blitz will be held at the Innovation Centre, 257 Collins Street Melbourne on June 3, 2010 at 4.30pm.

The event is free of charge to attend due to the support of Evado, Clinical Trials Software: [www.evado.com.au](http://www.evado.com.au) and IXC Intermediary Services: [www.ixc.com.au](http://www.ixc.com.au).

A wine, beer and cake event will follow in which to network and develop potential partnerships and collaborations.

Dr Palmer said about 100 people turn up for the seminars from academia, industry, government and clinicians.

Registration and inquiries should be directed to Dr Palmer [b.palmer@atecltd.com.au](mailto:b.palmer@atecltd.com.au).

## STIRLING PRODUCTS

Stirling Products says it has a partnership worth \$750,000 over five years with Kidney Health Australia.

Kidney Health Australia managing director Anne Wilson told Biotech Daily that Stirling would provide \$150,000 a year to her organization for five years.

In a media release to the ASX, Stirling Products said: "The partnering was announced yesterday at the launch of Kidney Health Week by Her Excellency the Governor-General of Australia Ms Quentin Bryce at Admiralty House in Sydney who also recognized a number of key contributors to Kidney Health Australia, including Mr Bob Pritchard, a consultant to Stirling Health and an Ambassador for Kidney Health Australia,".

The Office of the Governor-General said Ms Bryce launched Kidney Week but did not name Stirling Products and did not mention the partnership.

A spokesman for the Governor-General supplied a transcript of Ms Bryce's speech which honored Mr Pritchard's role as an ambassador for Kidney Health Australia.

Stirling said the \$750,000 partnership was "a major contribution that will help Kidney Health Australia address national community awareness of kidney related disease that claims the lives of over 50 Australians each and every day".

Stirling said the partnership would "underpin new Kidney Health Australia initiatives and will provide substantial mutual cross promotion and branding opportunities".

"It will also support the development of new products specifically for kidney patients through Stirling Health, the pharmacy products and marketing arm of Stirling Products in Australia," the company told the ASX.

Stirling said the parties would "shortly advise of the first of a product partnering that will be marketed throughout national pharmacies by Stirling Health, the company's recently launched pharmacy brand".

Stirling quoted the chair of Kidney Health Australia Vin Harink saying: "Kidney Health Australia relies on the support of the Australian community to underpin its work and the support of corporate partners like Stirling Products is crucial to our programs in early detection, prevention and management of kidney disease."

Stirling said Stirling Health had begun marketing "a range of clinically supported natural products that when combined with a healthy diet and exercise tackle chronic disease prevention and management".

Stirling chief executive officer Peter Boonen said the "inclusion of specifically targeted kidney health products is one of our current initiatives and we believe our Kidney Health Australia partnership is a wonderful opportunity for us to create an awareness of our new Stirling Health brand".

Stirling quoted of Kidney Health Australia managing director Anne Wilson saying that "at a time when over 50 people a day die of Kidney related disease in Australia, over 1000 others are on a four to seven year waitlist for a kidney transplant and a further 10,000 requiring dialysis just to stay alive, Stirling's wonderful contribution is a godsend to us".

"I can't express how much it is needed and how much it is appreciated," Ms Wilson was quoted as saying.

Stirling is the distributor of a Kiev-based over-the-counter product Immunoxel, which it has claimed is efficacious in a broad range of illnesses.

Stirling said it had also undertaken "a major sponsorship of the Australian Integrative Medicine Association".

Stirling said the sponsorship supported the integration of evidence-based complementary medicines within current mainstream medical practice.

Stirling fell 0.1 cents or 10 percent to 0.9 cents.

## CYCLOPHARM

Cyclopharm says it has Chinese regulatory approval to sell the Technegas Plus Generator.

Cyclopharm said there were about 400 nuclear medical centres in China.

Cyclopharm was untraded at 10 cents.

## BIOPROSPECT

Bioprospect says it will develop “new novel products and brands as part of the commercialization of natural Regen and Demure products”.

Bioprospect’s managing director Charles Pellegrino said the move would “facilitate the development of Re Gen Wellness Products into a successful, standalone business adding to the company’s natural product range”.

“Since acquiring Re Gen Wellness Products in August 2009, Bioprospect has moved quickly to commercialize its products based on natural Australian ingredients, including emu oil,” Mr Pellegrino said.

Bioprospect said the first product would be the Regen Pain Relief Spray, which has been developed for use by sufferers of arthritis and muscular and joint pain.

Bioprospect said the product had a “unique transdermal solvency which can achieve rapid and longer term benefits from the active components”.

Other products in the range include a Pain Relief Rub, Emu Oil Capsules, Pure Emu Oil and Massage Oil.

Mr Pellegrino said Regen was “a perfect fit within our natural product portfolio, and is confident of delivering returns from these exciting Australian products for the benefit of shareholders”.

Bioprospect fell 0.1 cents or 5.6 percent to 1.7 cents with 1.4 million shares traded.